SUNITINIB NEAPOLIS 50 MG BT 28
Product information
Metastatic renal cell carcinoma (MRCC): SUNITINIB NEAPOLIS is indicated for the treatment of advanced and/or metastatic renal cell cancers (MRCC) in adults.
Gastrointestinal stromal tumor (GIST): SUNITINIB NEAPOLIS is indicated for the treatment of non-resectable and/or metastatic gastrointestinal stromal tumors (GIST) in adults, after failure of treatment with imatinib due to resistance or intolerance.
Pancreatic neuroendocrine tumor (pNET): SUNITINIB NEAPOLIS is indicated for the treatment of non-resectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) with disease progression in adults.
We are working on other therapeutic areas
Learn more about our medicines
